Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Yan, Chen-Hua  [Clear All Filters]
2020
Tang F-F, Cheng Y-F, Xu L-P, Zhang X-H, Yan C-H, Han W, Chen Y-H, Huang X-J, Wang Y. cGVHD in pediatric haplo-HSCT. Biol Blood Marrow Transplant. 2020.
Zeng Q-Z, Zhang Y-Y, Wu Y-J, Zhang Z-Y, Zhang J-N, Fu H-X, Wang J-Z, Wang F-R, Yan C-H, Mo X-D, et al. Frequency, risk factors and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Tang F-F, Cheng Y-F, Xu L-P, Zhang X-H, Yan C-H, Han W, Chen Y-H, Huang X-J, Wang Y. The incidence, risk factors, and outcomes of acute graft-vs-host disease in pediatric T-cell-replete haploidentical hematopoietic stem cell transplantation. Pediatr Transplant. 2020:e13793.
Bai L, Cheng Y-F, Lu A-D, Suo P, Wang Y, Zuo Y-X, Yan C-H, Wu J, Jia Y-P, Sun Y-Q, et al. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia. Leuk Res. 2020;91:106333.
Liu S-N, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, et al. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute GVHD: updated experienced from a large-scale study. Am J Hematol. 2020.
Chang Y-J, Xu L-P, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, Yan C-H, et al. Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody. Bone Marrow Transplant. 2020.
2019
Ma R, Huang X-J, Xu L-P, Liu K-Y, Zhang X-H, Yan C-H, Han W, Wang F-R, Chen Y-H, Chen H, et al. Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Biol Blood Marrow Transplant. 2019.
Mo X-D, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, et al. Corrigendum to 'Interferon α: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation' [Biology of Blood and Marrow Transplantation 21/11 (2015) 19. Biol Blood Marrow Transplant. 2019.
Mo X-D, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, et al. Corrigendum to 'Interferon-α is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study' [Biology of Blood and Marrow Transplantation 23/8 (. Biol Blood Marrow Transplant. 2019.
Yan C-H, Liu Q-F, Wu D-P, Zhang X, Xu L-P, Zhang X-H, Wang Y, Huang H, Bai H, Huang F, et al. Corrigendum to 'Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus host disease guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractor. Biol Blood Marrow Transplant. 2019.
Zhang Y-Y, Mo X-D, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, et al. FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients. Bone Marrow Transplant. 2019.
Wang X-L, Han W, Zhao P, Liu X, Wang J-Z, Wang F-R, Yan C-H, Zhang Y-Y, Mo X-D, Wang Y, et al. Incidence, Risk Factors, Outcomes and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Wang X-Y, Fan Q-Z, Xu L-P, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, et al. The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. Cytometry B Clin Cytom. 2019.
Xue Y-J, Suo P, Huang X-J, Lu A-D, Wang Y, Zuo Y-X, Yan C-H, Wu J, Kong J, Zhang X-H, et al. Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukae. Br J Haematol. 2019.